Lausanne, Switzerland – April 20, 2016 – Saphetor SA, a Swiss precision medicine company working at the cutting edge of clinically meaningful genome-scale analysis based on Next Generation Sequencing (NGS), announced today that it has signed a collaboration agreement with the department of endocrinology, diabetes and metabolism of the Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois or CHUV), headed by Prof. Dr. Nelly Pitteloud. Under the agreement, Prof. Pitteloud’s department will use Saphetor’s precision medicine platform in research and clinical applications.
Prof. Pitteloud said: “The genetics underlying the multiple endocrine disorders that we research, diagnose and treat are extremely complex. The vast amount of NGS data that we generate through our research holds the key to significantly advance our understanding of these diseases, our ability to diagnose them, and contributes to the development of improved and tailored treatments. We believe that the analytical capabilities of Saphetor’s powerful and sophisticated next generation sequencing platform will help us find the key to many of these underserved diseases.”
Prof. Pitteloud focuses on translational research in the neuroendocrine and gonadal control of human reproduction, and the links between metabolism and reproduction. Her work on gonadotropin-releasing hormone (GnRH) deficiency has led to a number of landmark studies in the New England Journal of Medicine, the British Medical Journal, the Proceedings of the National Academy of Sciences, and several specialized research journals.
Andreas Massouras, CEO of Saphetor, said: “We are proud to start working with Professor Pitteloud, who is a leader in her field, and look forward to enable her team to further elucidate the genetic causes of GnRH deficiency and other endocrine disorders.”
Saphetor develops software and sophisticated analytical processes, using proprietary algorithms and trade secret know-how to identify genetic variants with greater accuracy and to give its clients access to seamlessly integrated data from a rapidly growing collection of genetic databases. To date, Saphetor has already aggregated more than 20 leading databases, representing more than 13 billion genetic variant annotations. Saphetor’s competitive advantage is its unique ability to combine data integration with annotation and interpretation in an interface that is intuitive and easy to navigate
Founded in 2014, Saphetor is a precision medicine company at the cutting edge of genome-scale analysis based on Next Generation Sequencing (NGS). Capitalizing on the emerging trend in NGS to use large “panels” of genes, exomes, or whole genomes, Saphetor’s suite of services offers clinicians intuitive, data-driven solutions to make faster, more accurate diagnoses, and informed decisions for the selection of the best therapies, especially for cancer and difficult to diagnose conditions, such as rare diseases or cognitive impairment. For more information: www.saphetor.com